Table 2.
Medication use over time for patients alive on support at each follow-up period based on mean arterial pressure. The Supplemental Table 1 online shows similar results for blood pressure assessed by Doppler and systolic blood pressure.
| Combined Cohort |
MAP ≤75 mmHg |
MAP 76-90 mmHg |
MAP 91-100 mmHg |
MAP >100 mmHg |
p* | |
|---|---|---|---|---|---|---|
| 1 month | ||||||
| ACE-I (n=7671) | 32% | 32.6% | 31.6% | 32.0% | 34.5% | 0.62 |
| ARB (n=7667) | 6.3% | 4.6% | 6.5% | 7.4% | 7.3% | 0.013 |
| β -blocker (n=7678) | 51.6% | 46.7% | 52.0% | 54.7% | 56.7% | <0.001 |
| Digoxin (n=6689) | 22.0% | 21.3% | 22.5% | 22.8% | 16.9% | 0.075 |
| Calcium CB (n=6674) | 7.9% | 6.5% | 7.8% | 9.4% | 9.8% | 0.033 |
| Hydralazine (n=6677) | 18.8% | 15.5% | 18.2% | 23.0% | 25.1% | <0.001 |
| Loop Diuretic (n=7674) | 70.2% | 68.1% | 70.3% | 71.6% | 71.8% | 0.18 |
| Aldo-I (n=7674) | 32% | 34.5% | 32.7% | 29.2% | 31.5% | 0.029 |
| Inotrope (n=3874) | 9.8% | 17.6% | 8.4% | 6.0% | 6.3% | <0.001 |
| 6mo | ||||||
| ACE-I (n=7922) | 42.1% | 44.0% | 41.4% | 42.9% | 40.7% | 0.30 |
| ARB (n=7901) | 10.2% | 9.0% | 10.0% | 10.4% | 14.6% | 0.005 |
| β-blocker (n=7920) | 68.8% | 67.6% | 68.3% | 70.9% | 70.6% | 0.15 |
| Digoxin (n=6084) | 21.0% | 22.1% | 21.3% | 20.6% | 15.2% | 0.044 |
| Calcium CB (n=6069) | 8.6% | 12.6% | 11.3% | 15.3% | 18.2% | <0.001 |
| Hydralazine (n=6079) | 19.8% | 14.3% | 18.9% | 25.1% | 30.1% | <0.001 |
| Loop Diuretic (n=7910) | 66.8% | 66.8% | 66.6% | 66.5% | 68.7% | 0.83 |
| Aldo-I (n=7911) | 35.7% | 38.6% | 36.2% | 32.3% | 32.1% | 0.001 |
| Inotrope (n=4456) | 2.0% | 4.7% | 1.7% | 1.3% | 0.0% | <0.001 |
| 1 Year | ||||||
| ACE-I (n=5749) | 41.5% | 43.0% | 40.8% | 42.6% | 40.7% | 0.57 |
| ARB (n=5736) | 12.2% | 10.5% | 11.8% | 13.2% | 16.5% | 0.017 |
| β-blocker (n=5752) | 73.6% | 71.4% | 73.2% | 75.3% | 78.0% | 0.052 |
| Digoxin (n=4678) | 19.8% | 19.4% | 21.0% | 17.5% | 14.6% | 0.017 |
| Calcium CB (n=4654) | 15.1% | 11.5% | 14.2% | 19.9% | 19.9% | <0.001 |
| Hydralazine (n=4670) | 21.5% | 17.3% | 19.4% | 28.5% | 33.1% | <0.001 |
| Loop Diuretic (n=5743) | 66.4% | 66.5% | 66.2% | 66.7% | 66.9% | 0.99 |
| Aldo-I (n=5745) | 34.9% | 37.3% | 35.5% | 31.7% | 32.2% | 0.034 |
| Inotrope (n=2980) | 1.3% | 2.7% | 1.2% | 0.8% | 0.5% | 0.029 |
| 2 Years | ||||||
| ACE-I (n=3066) | 39.6% | 43.2% | 38.8% | 40.3% | 37.0% | 0.32 |
| ARB (n=3061) | 13.8% | 12.8% | 13.4% | 14.6% | 17.9% | 0.30 |
| β-blocker (n=3071) | 77.9% | 77.0% | 77.1% | 80.5% | 79.5% | 0.35 |
| Digoxin (n=2751) | 19.6% | 21.1% | 21.0% | 16.6% | 11.6% | 0.007 |
| Calcium CB (n=2733) | 17.5% | 13.1% | 15.5% | 25.1% | 23.9% | <0.001 |
| Hydralazine (n=2743) | 24.4% | 18.1% | 22.6% | 32.2% | 33.7% | <0.001 |
| Loop Diuretic (n=3066) | 65.4% | 64.8% | 66.0% | 63.3% | 66.3% | 0.67 |
| Aldo-I (n=3602) | 33.7% | 37.8% | 35.0% | 29.4% | 24.3% | 0.001 |
| Inotrope (1304) | 1.3% | 1.6% | 1.2% | 1.1% | 2.4% | 0.78 |
| 3 Years | ||||||
| ACE-I (n=1608) | 39.3% | 41.9% | 39.7% | 38.3% | 33.3% | 0.50 |
| ARB (n=1607) | 13.4% | 12.1% | 13.1% | 14.1% | 17.1% | 0.62 |
| β-blocker (n=1610) | 79.2% | 80.5% | 77.8% | 80.1% | 87.6% | 0.11 |
| Digoxin (n=1544) | 18.8% | 23.5% | 20.4% | 13.9% | 8.8% | 0.001 |
| Calcium CB (n=1531) | 16.3% | 10.7% | 14.7% | 22.6% | 25.2% | <0.001 |
| Hydralazine (n=1534) | 23.9% | 14.8% | 22.0% | 31.9% | 36.3% | <0.001 |
| Loop Diuretic (n=1597) | 63.6% | 61.6% | 63.5% | 62.3% | 72.4% | 0.25 |
| Aldo-I (n=1607) | 29.9% | 33.0% | 31.5% | 25.9% | 20.0% | 0.025 |
| Inotrope (n=512) | 1.0% | 1.5% | 1.0% | 1.0% | 0.0% | 0.93 |
| 4 Years | ||||||
| ACE-I (n=772) | 35.6% | 37.5% | 37.3% | 30% | 32.7% | 0.39 |
| ARB (n=775) | 14.5% | 15.0% | 14.1% | 16.0% | 12.2% | 0.91 |
| β-blocker (n=775) | 79.5% | 79.0% | 79.6% | 78.7% | 81.6% | 0.98 |
| Digoxin (n=773) | 20.8% | 25.0% | 23.1% | 12.7% | 16.3% | 0.029 |
| Calcium CB (n=764) | 15.7% | 13.0% | 13.1% | 21.3% | 28.6% | 0.006 |
| Hydralazine (n=768) | 23.0% | 9.0% | 22.2% | 27.3% | 40.8% | <0.001 |
| Loop Diuretic (n=767) | 64.7% | 65.4% | 63.1% | 68.0% | 68.8% | 0.66 |
| Aldo-I (n=773) | 31.8% | 40.0% | 32.9% | 26.8% | 22.4% | 0.092 |
| Inotrope (n=140) | 0.7% | 0% | 1.1% | 0% | 0% | 0.90 |
*
Pearson’s Chi Square p value comparing MAP categories. n represents number of patients with available data for each time point for use or non-use of each medication. ACE-I= angiotensin-converting enzyme inhibitor; ARB= angiotensin receptor antagonist; Aldo-I= aldosterone inhibitor; CB= channel blocker.